Source comparison
CJC-1295 No DAC & Ipamorelin vs IGF-1 LR3: Research Application Comparison
Mechanism Upstream: stimulates pituitary GH release via GHRH and ghrelin receptor agonism Downstream: direct IGF-1 receptor activation, bypasses pituitary CJC/Ipa preserves natural feedback; IGF-1 LR3 replaces it Half-Life 30 min (CJC no DAC), 2 hours (Ipamore
This comparison does not assign a generated winner or score.
- Mechanism
- Upstream: stimulates pituitary GH release via GHRH and ghrelin receptor agonism
- Downstream: direct IGF-1 receptor activation, bypasses pituitary
- CJC/Ipa preserves natural feedback; IGF-1 LR3 replaces it
- Half-Life
- 30 min (CJC no DAC), 2 hours (Ipamorelin)
- 20–30 hours
- Short half-lives mimic natural pulses; IGF-1 LR3 provides constant elevation
- Dosing Frequency
- 1–3x daily, 100–200 mcg each peptide
- 1x daily, 20–60 mcg
- More frequent injections vs single daily dose
- Suppression Risk
- Minimal. Preserves endogenous GH pulsatility
- Moderate to high. Suppresses GH axis with prolonged use
- CJC/Ipa safer for long-term research; IGF-1 LR3 requires recovery phase
- Anabolic Potency
- Indirect via GH-induced hepatic IGF-1 synthesis
- Direct. Immediately activates IGF-1 receptors in muscle tissue
- IGF-1 LR3 produces faster protein synthesis response
- Metabolic Benefits
- Lipolysis, insulin sensitivity modulation, immune function (via pulsatile GH)
- Primarily anabolic. Less pronounced metabolic or immune impact
- CJC/Ipa offers broader physiological benefits beyond muscle
- Recovery Timeline
- 7–10 days to baseline after cessation
- 3–6 weeks for GH axis recovery depending on cycle length
- CJC/Ipa allows immediate follow-on protocols; IGF-1 LR3 requires washout
- Ideal Research Context
- Long-term protocols (12+ weeks), body recomposition studies, collagen synthesis research
- Short-term anabolic research (4–6 weeks), muscle hypertrophy studies, injury recovery models
- Match mechanism to timeline and research goals